| (Values in U.S. Thousands) | Nov, 2025 | Nov, 2024 | Nov, 2023 | Nov, 2022 | Nov, 2021 |
| Sales | 83,980 | 54,550 | 76,990 | 38,630 | 29,750 |
| Sales Growth | +53.95% | -29.15% | +99.30% | +29.85% | +66.95% |
| Net Income | -264,460 | -193,570 | -143,950 | -180,360 | -117,190 |
| Net Income Growth | -36.62% | -34.47% | +20.19% | -53.90% | -171.02% |
Nurix Therapeutics Inc
(NRIX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.
Fiscal Year End Date: 11/30